Try our Advanced Search for more refined results
Sentry Data Systems, Inc. v. CVS Health et al
Case Number:
0:18-cv-60257
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 16, 2019
Sentry Data, CVS Reach Deal In Antitrust Fight
Health data and analytics provider Sentry Data Systems has reached a settlement with CVS over its claims that the pharmacy giant is trying to strong-arm it out of the market with the acquisition of rival data company Wellpartner LLC.
-
September 03, 2019
CVS Mad About Findings, Not Discovery Pace, Sentry Says
Health data and analytics provider Sentry Data Systems lashed out Monday at CVS's accusations of discovery heel-dragging, telling a Florida federal court the pharmacy chain is only trying to delay Sentry's antitrust suit because it's unhappy with how the case is shaping up.
-
August 23, 2019
CVS Says Sentry's Heel-Dragging On Doc Production 'Tactical'
Health data and analytics provider Sentry Data Systems is failing to make good on promises regarding document production in an antitrust suit accusing former partner CVS Pharmacy of trying to strongarm it out of the market with an acquisition of rival Wellpartner, CVS told a Florida federal court Thursday.
-
May 21, 2019
CVS Defends Contract Counterclaim In Sentry Antitrust Suit
Sentry Data Systems Inc. cannot duck a breach of contract counterclaim accusing it of botching its performance as CVS' administrator for a federal program for discounted drugs, the pharmacy giant told a Florida federal judge Monday.
-
April 03, 2019
CVS Loses Challenge To Sentry's Revamped Antitrust Suit
Sentry Data Systems Inc. can continue its lawsuit against CVS alleging the pharmacy chain is unlawfully forcing health care providers to use its 340B Drug Pricing Program administrator Wellpartner LLC, a Florida federal judge said on Wednesday.
-
August 28, 2018
CVS Ducks Sentry Data's Antitrust Claim, For Now
A Florida federal judge on Tuesday dismissed an antitrust claim from Sentry Data Systems Inc. alleging CVS is unlawfully forcing health care providers to use its 340B Drug Pricing Program administrator Wellpartner LLC, but left intact allegations the pharmacy giant misappropriated trade secrets to steal customers.